



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien T.J. § ART UNIT:  
§ 1642  
FILED: July 13, 2001 §  
§ EXAMINER:  
S SERIAL NO.: 09/905,083 § Blanchard, David.  
§  
FOR: Method of Inducing Immunity §  
Against Stratum Corneum § DOCKET:  
Chymotryptic Enzyme § D6223CIP/C/D

MS RCE  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE  
PATENTING REJECTION OVER A PENDING SECOND APPLICATION**

The owner, The Board of Trustees of University of Arkansas System, of 100 percent interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. Sections 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 10/372,521, filed on February 21, 2003. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal

disclaimer filed prior to the present grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 or Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

Please charge the \$55 fee required under 37 CFR §1.20(d) to credit card identified on the enclosed PTO-2038.

Respectfully submitted,



Benjamin Aaron Adler, Ph.D., J.D.  
Registration No. 35,423

Date: May 1, 2005  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 777-2321  
BADLER1@houston.rr.com